{
    "root": "191b4856-1662-a7b8-e063-6394a90a2c56",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pitavastatin",
    "value": "20240523",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM OXIDE",
            "code": "3A3U0GI71G"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "PITAVASTATIN CALCIUM",
            "code": "IYD54XEG3W"
        }
    ],
    "indications": "Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n                  \n                     Adult with primary hyperlipidemia.\n                     Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).",
    "contraindications": "Take orally once daily with or without food at the same time each day ( 2.1 ). For patients requiring a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment. ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiation of pitavastatin tablets, and adjust the dosage if necessary. ( 2.1 ). Recommended dosage is 2 mg to 4 mg once daily. Maximum recommended dosage is 4 mg once daily. ( 2.2 ) Recommended starting dosage for patients with moderate and severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily. Maximum recommended dosage is 2 mg once daily. ( 2.3 ) See full prescribing information for pitavastatin tablets dosage modifications due to drug interactions. ( 2.4 )",
    "warningsAndPrecautions": "Pitavastatin tablets for oral administration are provided as white to off-white circular biconvex film-coated tablets that contain 1 mg, 2 mg, or 4 mg of pitavastatin. Each tablet has “OP” debossed on one side and a code number specific to the tablet strength on the other.\n                  \n                  \n                     \n                     Packaging\n                     \nPitavastatin tablets are supplied as:\n \n                  \n                     1 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo “OP” on one side and “57” on the other side.\n                  \n                  　Supplied as follows:\n                   　　NDC 0480-3631-98; HDPE bottles of 90 tablets\n                  \n                     2 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo “OP” on one side and “58” on the other side.\n                  \n                  　Supplied as follows:\n                  　　NDC 0480-3632-98; HDPE bottles of 90 tablets\n                  \n                     4 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo “OP” on one side and “59” on the other side.\n                  \n                  　Supplied as follows:\n                  　　NDC 0480-3633-98; HDPE bottles of 90 tablets\n                  \n                  \n                     Storage\n                     \nStore at 25°C (77° F), excursions permitted from 15°C-30°C (59°F-86°F). [See USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions": "Pitavastatin tablets are contraindicated in the following conditions:\n                  \n                     Concomitant use of cyclosporine\n    [see Drug Interactions (\n                        7\n                        )].\n  \n                     Acute liver failure or decompensated cirrhosis \n   [see Warning and Precautions (\n                        5.3\n                        )].\n                     \n                     Hypersensitivity to pitavastatin or any excipients in pitavastatin tablets. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets \n   [see Adverse Reactions (\n                        6\n                        )]."
}